Adiponectin exerts its effect through adiponectin receptor 1 and 2, which are both expressed in the heart in vivo [
5] and in the cardiomyocyte in vitro [
4]. Adiponectin receptors were also expressed in atherosclerotic lesions, macrophages and vascular endothelial cells [
5,
25]. Overweight patients with coronary artery disease had decreased surface expression of adiponectin receptors in peripheral monocytes [
26]. Although the protein expression of adiponectin receptor 1 in coronary arterioles and aortas was similar between control and diabetic mice, the protein expression of adiponectin receptor 2 was significantly reduced in type 2 diabetic mice [
27]. Adenovirus-mediated overexpression of AdipoR1 and 2 in vascular endothelial cells significantly enhanced the antiinflammatory effect of adiponectin [
28]. Our study showed that the expression of adipoR2 in the heart and the expression of adipoR1 in aorta were decreased in diabetic rats. The decreased adiponectin receptors may be due to hyperinsulinemia since it has been reported that insulin deficiency increased, but insulin replenishment decreased the expression of adipoR1/2 in animals in vivo [
29]. The decreased adiponectin and its receptors may lead to adiponectin resistance, which may limit adiponectin to produce its biological effects, especially its protective effect on diabetic heart and aorta. The decreased adiponectin and its receptors may together play a role in the occurrence and progression of cardiomyopathy and atherosclerosis in type 2 diabetic rats. Adiponectin receptors could be modulated by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR [
25]. Our study showed that telmisartan, a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity [
16,
17], increased the mRNA expression of AdipoR2 in the heart and the mRNA expression of AdipoR1 in the aorta in diabetic rats, indicating that angiotensin II could down-regulate, while PPARgamma agonist could up-regulate the expression of adiponectin receptors. The results of our study are in agreement with the results of studies [
25,
30] showing that adiponectin receptors were expressed in adult ventricular cardiomyocytes, atherosclerotic lesions and macrophages, and upregulated by activation of peroxisome proliferator-activated receptor gamma.
Adiponectin can improve both glucose metabolism and insulin resistance [
31]. Glucose enters the heart via the facilitative glucose transporters GLUT1 and GLUT4 [
32]. Glucose transporter expression in the heart is altered in various pathological states. Our study showed that the mRNA expression of GLUT4 was decreased, indicating that glucose metabolism would be reduced in diabetic rat hearts. It was reported that changes in glucose transporter expression contributed to myocardial dysfunction in diabetes [
33]. In addition, GLUT4-deficient mice developed striking cardiac hypertrophy [
34]. Normalization of glucose homeostasis by transgenic re-expression of GLUT4 in the skeletal muscle resulted in a reversal of the cardiac pathology in mice heterozygous for GLUT4 ablation [
35]. Hence, we propose that the decreased cardiac GLUT4 observed in this study may contribute to the deterioration in heart function and to the cardiac hypertrophy seen in diabetic rats. Our study showed that telmisartan treatment reduces cardiac hypertrophy, improved the heart function, and increased myocardial expression of GLUT4 in diabetic rats. The increased adiponectin and its receptors may partly explain the increased GLUT4, which may contribute to the ameliorated heart function in diabetic rats treated with telmisartan.